WHO Advances Vaccinations Trials for Bundibugyo Ebola Outbreak
WHO has convened expert and advisory groups to assess candidate vaccinations and therapeutics for Bundibugyo virus disease as Ebola disease spreads in the Democratic Republic of the Congo, with cases also reported in Uganda. The agency said the products it identified should be used only in clinical trials, pushing the outbreak response toward research as well as containment.
The move centers on a simple constraint: there are no licensed therapeutics or vaccines specifically approved for prevention and treatment of Bundibugyo virus disease. WHO said several candidate products are promising enough to prioritize for evaluation, but the advisory groups recommended that all of the products considered be used exclusively within clinical trials.
WHO R&D Blueprint meetings
WHO convened meetings with the WHO R&D Blueprint technical advisory groups on candidate vaccines and therapeutics for Bundibugyo virus disease, along with the Strategic Advisory Group of Experts on Immunization and its Ebola vaccine working group. SAGE and its Ebola vaccine working group advised on the potential role of licensed Ebola vaccines during Bundibugyo virus disease outbreaks, while WHO described the R&D Blueprint as a global initiative to rapidly activate research and development activities during epidemics.
WHO is working with the governments of the Democratic Republic of the Congo and Uganda to facilitate research evaluation of the products. WHO, the two governments, Africa CDC, ANRS Emerging infectious diseases, and other scientific partners are developing and implementing protocols to assess the safety and efficacy of the prioritized therapeutics through clinical field trials.
Democratic Republic of the Congo and Uganda
The outbreak spans the Democratic Republic of the Congo, where the current outbreak is taking place, and Uganda, where cases have also been reported. WHO said the priority remains stopping transmission through disease surveillance, rapid testing and diagnosis, contact tracing, isolation and care for patients, infection prevention and control, community engagement, and safe and dignified burials.
WHO also called for accelerated access to essential supplies, stronger community protection, engagement and trust, and coordinated investment in the research, development and evaluation of Bundibugyo virus disease countermeasures. WHO said all research must adhere to the highest ethical standards under the leadership of national health authorities and in close consultation with affected communities.
Clinical trials only
The friction point is practical and immediate: WHO and its advisory groups see enough promise in the candidate products to move them into evaluation, but not enough to authorize routine use. That means the path to evidence runs through clinical field trials, not broad deployment, and the outcomes will depend on the protocols now being built with national health authorities and scientific partners.
For people in the Democratic Republic of the Congo and Uganda, the next step is not a public rollout of a licensed Ebola vaccine or treatment for Bundibugyo virus disease. It is a research process aimed at determining whether the prioritized products are safe and effective enough to change that status.
